Niagen Bioscience, Inc. (NAGE)

Market Cap	738.06M
Revenue (ttm)	107.93M
Net Income (ttm)	14.11M
Shares Out	78.94M
EPS (ttm)	0.18
PE Ratio	52.24
Forward PE	86.33
Dividend	n/a
Ex-Dividend Date	n/a

Volume	754,756
Open	9.54
Previous Close	9.53
Day's Range	9.22 - 9.61
52-Week Range	2.53 - 14.69
Beta	2.14
Analysts	Strong Buy
Price Target	16.67 (+78.29%)
Earnings Date	Aug 6, 2025

About AKYA

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and ph...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 104
• Stock Exchange: NASDAQ
• Ticker Symbol: NAGE
• Website: https://www.niagenbioscience.com

Analyst Summary

According to 3 analysts, the average rating for NAGE stock is "Strong Buy." The 12-month stock price target is $16.67, which is an increase of 78.29% from the latest price.

Price Target

$16.67

(78.29% upside)

Analyst Consensus: Strong Buy